Torrent Pharmaceuticals has accepted the resignation of Executive Director Amal Kelshikar, effective at the close of business on October 16, 2026. According to reports from Live Mint, the resignation was filed under Regulation 30 of SEBI Listing Regulations. In his resignation letter addressed to the company's managing director, Kelshikar stated that the decision was made after thoughtful reflection and while it was difficult given his enjoyment of the role, he believed it was the right time to transition.
As reported by boardstewardship.com, Amal Kelshikar brings nearly three decades of professional experience to his role at Torrent Pharmaceuticals. His career began at Novartis India as head of strategic planning/business development, followed by positions at Novartis Singapore as head of Mature Products BU/BDL - Asia Pacific and commercial director of Novartis Philippines. He subsequently joined Baxter Healthcare as general manager and served as president of AstraZeneca's Philippines subsidiary. Kelshikar joined Abbott in May 2012 as Managing Director and General Manager of the India region, later becoming Abbott's Singapore General Manager and Divisional Vice President, Asia Pacific. At Abbott Nutrition, he quadrupled sales in India, while at Baxter Philippines, he turned around an underperforming business and restored profitability.
According to Live Mint, Kelshikar holds an Executive Marketing Program from the Kellogg Executive Education and completed his undergraduate course in chemical engineering from the University Department of Chemical Technology, Mumbai. He also earned his MBA (PGDM) in marketing, finance, and strategy from the IIM Ahmedabad. In May 2022, he joined Torrent Pharmaceuticals as its Executive Director. Additionally, as reported by boardstewardship.com, he has completed executive education programmes in finance at Harvard Business School and in marketing at Kellogg Executive Education.
As reported by Live Mint, Kelshikar expressed sincere gratitude to management and colleagues for their support throughout his association with the company, including during his extended tenure beyond superannuation. He stated that the experience, responsibilities, and opportunities entrusted to him over the years have been immensely valuable and contributed meaningfully to his professional and personal journey. Kelshikar added that he remains deeply grateful for the opportunity to be part of the company and will always value the relationships, experiences, and memories gained during his tenure, while committing to support a smooth transition and complete all handover formalities.
